|
Comparison and performance of three plasma next-generation sequencing assays versus tissue testing for the detection of actionable driver mutations in advanced non-squamous non-small cell lung carcinoma. |
| |
|
Honoraria - Amgen; AstraZeneca; Biocartis; BMS GmbH & Co. KG; Janssen; Pfizer; Pierre Fabre; Roche; Thermo Fisher Scientific |
Consulting or Advisory Role - Amgen; AstraZeneca; Biocartis; BMS GmbH & Co. KG; Janssen; Pfizer; Pierre Fabre; Roche; Thermo Fisher Scientific |
Research Funding - Amgen; AstraZeneca; Biocartis; Thermo Fisher Scientific |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Biocartis; BMS GmbH & Co. KG; Janssen; Pfizer; Pierre Fabre; Roche; Thermo Fisher Scientific |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Sanofi; Takeda |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Merck |
Speakers' Bureau - AstraZeneca |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
No Relationships to Disclose |